Turmeric may be as good for treating indigestion as drug to curb excess stomach acid
A natural compound found in the culinary spice turmeric may be as effective as omeprazole - a drug used to curb excess stomach acid—for treating indigestion symptoms, suggests the first study of its kind, published online in the journal BMJ Evidence-Based Medicine.
Turmeric is derived from the root of the Curcuma longa plant. It contains a naturally active compound called curcumin thought to have anti-inflammatory and antimicrobial properties, and has long been used as a medicinal remedy, including for the treatment of indigestion, in South East Asia. (Source: World Pharma News)
Source: World Pharma News - September 12, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants
Today, the U.S. Food and Drug Administration took action approving and authorizing for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death. Today's actions relate to updated mRNA vaccines for 2023-2024 manufactured by ModernaTX Inc. and Pfizer Inc. (Source: World Pharma News)
Source: World Pharma News - September 11, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Antidepressant use in people with both physical health problems and depression
Many people with diseases such as cancer or diabetes or those who have had a heart attack or stroke also suffer from depression. How effective are antidepressants for these patients? And are they just as safe for these people as for those without physical health problems? Researchers from Charité - Universitätsmedizin Berlin and Aarhus University in Denmark have teamed up to investigate these questions. (Source: World Pharma News)
Source: World Pharma News - September 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
A free online tool can help prostate cancer patients save on out-of-pocket drug costs
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds.
For patients enrolled in Medicare Part D prescription drug plans, out of pocket costs can vary significantly. But by using an online Medicare plan finder tool, patients can compare pricing among all Part D drug plans offered in their area and select the most affordable plan. (Source: World Pharma News)
Source: World Pharma News - September 7, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Roche & #039;s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - September 6, 2023 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
First-in-class targeted microRNA therapy slows cancer tumor growth
A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated with the new therapy did not increase in size over the course of a 21-day study, while untreated tumors tripled in size over the same time period.
Cancer can begin almost anywhere in the human body. It is characterized by cells that divide uncontrollably and that may be able to ignore signals to die or stop dividing, and even evade the immune system. (Source: World Pharma News)
Source: World Pharma News - September 5, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Why breast cancer survivors don & #039;t take their medication, and what can be done
For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they take medication to block sex hormones, which can fuel tumor growth and spark recurrence.
The drugs are life-saving: They've been shown to cut risk of cancer recurrence by as much as half in patients with hormone receptor-positive tumors (HR+) - the most common form of breast cancer. (Source: World Pharma News)
Source: World Pharma News - September 4, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Statins linked to lower risk of colorectal cancer in patients with ulcerative colitis
Cholesterol-lowering statins might protect patients with ulcerative colitis from developing and dying from colorectal cancer. Statin treatment was also associated with a lower risk of death regardless of cause in patients with ulcerative colitis or Crohn's disease. This is according to a study by researchers at Karolinska Institutet in Sweden published in eClinicalMedicine. (Source: World Pharma News)
Source: World Pharma News - September 1, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
How Unique Immune Cells can Recognize - and destroy - Tumors
Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells. Cancer patients with higher levels of these T cells in their tumors tend to fare better than those with lower levels. But scientists have struggled to understand exactly how gamma delta T cells can recognize cancerous cells, and how new cancer therapies may be able to take advantage of these powerful immune cells. (Source: World Pharma News)
Source: World Pharma News - August 31, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
BlueRock & #039;s Phase I study with bemdaneprocel in patients with Parkinson & #039;s disease meets primary endpoint
Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark. (Source: World Pharma News)
Source: World Pharma News - August 30, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Drug that targets scar-like tissue in tumours shows promise for aggressive pancreatic cancer
Findings from the Garvan Institute of Medical Research reveal a new Australian drug that targets scar-like 'fibrotic' tissue within tumours shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer with a five-year survival rate of less than 10%.
The research in mouse models showed that when given in combination with chemotherapy, the drug PXS-5505 increased survival time by more than 35%, compared to chemotherapy treatment alone. (Source: World Pharma News)
Source: World Pharma News - August 29, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Novartis completes acquisition of Chinook Therapeutics
Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion. (Source: World Pharma News)
Source: World Pharma News - August 28, 2023 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
New & #039;promising medicines & #039; fund may incentivise commercialisation of high price drugs with weak evidence on clinical benefits
A new fund to fast-track patient access to potentially valuable new medicines may incentivise the pharmaceutical industry to develop high priced drugs for rare diseases with weak evidence on clinical benefits.
Health economics and policy academics from the London School of Hygiene & Tropical Medicine (LSHTM), writing in the Journal of the Royal Society of Medicine, warn that if the NHS England Innovative Medicines Fund (IMF) is not implemented appropriately, it risks disincentivising the generation of essential evidence and could shift the financial burden from the pharmaceutical industry to the public finances. (Source: World Pharma News)
Source: World Pharma News - August 25, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Researchers decode new antibiotic
More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the world are searching for new effective substances. Researchers from the University of Bonn, the German Center for Infection Research (DZIF), Utrecht University (Netherlands), Northeastern University in Boston (USA) and the company NovoBiotic Pharmaceuticals in Cambridge (USA) now have discovered and deciphered the mode of action of a new antibiotic. (Source: World Pharma News)
Source: World Pharma News - August 24, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
U.S. FDA Approves ABRYSVO ™, Pfizer & #039;s vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. (Source: World Pharma News)
Source: World Pharma News - August 23, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
